Health Care › Biological Products (No Diagnostic Substances)
AIM Price Correlated With Financials For AIM ImmunoTech
Free historical financial statements for AIM Immunotech Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with AIM stock chart to see long term trends.
ImmunoTech Inc. and its subsidiaries (collectively, “AIM”, “Company”, “we” or “us”) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for
commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (“CFS”).
Company’s primary present business focus involves Ampligen. Ampligen is a double-stranded RNA (“dsRNA”) molecule being
developed for globally important cancers, viral diseases and disorders of the immune system.
currently is proceeding primarily in three areas:
plus Standard of Care (“SOC”) to treat pancreatic cancer patients, and in other
cancers, as a potential therapeutic that modifies the tumor microenvironment with the goal
of increasing anti-tumor responses to check point inhibitors and with SOC.
Ampligen’s antiviral activities and potential use as a prophylactic or treatment for
existing viruses, mutations thereof or new viruses.
as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (“ME/CFS”)
and what we refer to as Post-COVID-19 Cognitive Impairment.
some two years after COVID-19 first appeared, the world has a number of vaccines and some promising therapeutics. AIM’s quest to
prove the antiviral activities of Ampligen continues. If Ampligen has the broad-spectrum antiviral properties that the Company believes
that it has, it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that
arise in the future. Unlike most developing therapeutics which attack the virus, Ampligen works differently. AIM believes that it activates
antiviral immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well.
N Injection is approved in Argentina for a category of sexually transmitted disease infections and patients that are not responsive or
are intolerant to recombinant interferon. Alferon N Injection is the only natural-source, multi-species alpha interferon currently approved
for sale in the United States for the intralesional treatment of refractory (i.e., resistant to other treatment) or recurring external
condylomata acuminata/genital warts in patients 18 years of age or older. Certain types of human papilloma viruses cause genital warts.
AIM also has approval from ANMAT for the treatment of refractory patients that failed or were intolerant to treatment with recombinant
interferon in Argentina.
Company recently announced the sale of its 30,000
sq. ft. facility at 783 Jersey
Ave, New Brunswick, N.J., where it conducts testing and has produced limited quantities of active pharmaceutical ingredients (“API”)
for its products. While the Company believes it has sufficient API to meet its current needs, it is also continually exploring new opportunities
to maximize its ability to fulfill future needs. AIM’s current and active produc